Mitsuaki Machida

539 total citations · 1 hit paper
7 papers, 425 citations indexed

About

Mitsuaki Machida is a scholar working on Pharmacology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Mitsuaki Machida has authored 7 papers receiving a total of 425 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Pharmacology, 3 papers in Pulmonary and Respiratory Medicine and 3 papers in Epidemiology. Recurrent topics in Mitsuaki Machida's work include Antibiotics Pharmacokinetics and Efficacy (3 papers), Respiratory and Cough-Related Research (3 papers) and Urinary Tract Infections Management (2 papers). Mitsuaki Machida is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (3 papers), Respiratory and Cough-Related Research (3 papers) and Urinary Tract Infections Management (2 papers). Mitsuaki Machida collaborates with scholars based in Japan, United Kingdom and United States. Mitsuaki Machida's co-authors include Tsutae Den Nagata, Simon Portsmouth, Roger Echols, Juan Camilo Arjona Ferreira, Mari Ariyasu, David van Veenhuyzen, Péter Tenke, Hiroyuki Ishihara, Akio Niimi and Tadashi Kamei and has published in prestigious journals such as European Respiratory Journal, The Lancet Infectious Diseases and Clinical Therapeutics.

In The Last Decade

Mitsuaki Machida

7 papers receiving 413 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial

2018 305 citations Simon Portsmouth, David van Veenhuyzen et al. The Lancet Infectious Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mitsuaki Machida Japan	6	275	212	125	111	70	7	425
Patrizia Murino Italy	9	349 1.3×	241 1.1×	144 1.2×	206 1.9×	44 0.6×	13	565
F. Rossi Italy	10	133 0.5×	81 0.4×	77 0.6×	109 1.0×	271 3.9×	40	598
O. O. Lyulko Germany	4	233 0.8×	171 0.8×	122 1.0×	96 0.9×	34 0.5×	4	317
Evangelos Vryonis Greece	7	190 0.7×	100 0.5×	67 0.5×	80 0.7×	5 0.1×	11	300
David van Veenhuyzen United States	5	254 0.9×	208 1.0×	121 1.0×	130 1.2×	20 0.3×	7	392
Stephanie Durso Italy	8	156 0.6×	171 0.8×	55 0.4×	84 0.8×	12 0.2×	9	305
Islam M. Ghazi United States	10	197 0.7×	129 0.6×	101 0.8×	96 0.9×	15 0.2×	35	320
Aniello Alfieri Italy	11	125 0.5×	91 0.4×	72 0.6×	55 0.5×	5 0.1×	32	275
Matias Chiarastelli Salomão Brazil	9	138 0.5×	46 0.2×	68 0.5×	158 1.4×	35 0.5×	17	436
Marlynne Micalizzi United States	4	230 0.8×	222 1.0×	56 0.4×	85 0.8×	27 0.4×	6	367

Countries citing papers authored by Mitsuaki Machida

Since Specialization

Citations

This map shows the geographic impact of Mitsuaki Machida's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mitsuaki Machida with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mitsuaki Machida more than expected).

Fields of papers citing papers by Mitsuaki Machida

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mitsuaki Machida. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mitsuaki Machida. The network helps show where Mitsuaki Machida may publish in the future.

Co-authorship network of co-authors of Mitsuaki Machida

This figure shows the co-authorship network connecting the top 25 collaborators of Mitsuaki Machida. A scholar is included among the top collaborators of Mitsuaki Machida based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mitsuaki Machida. Mitsuaki Machida is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

McGarvey, Lorcan, John A. Smith, Alyn H. Morice, et al.. (2022). A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2b Trial of P2X3 Receptor Antagonist Sivopixant for Refractory or Unexplained Chronic Cough. Lung. 201(1). 25–35. 29 indexed citations

2.

Niimi, Akio, Junpei Saito, Tadashi Kamei, et al.. (2021). Randomised trial of the P2X₃receptor antagonist sivopixant for refractory chronic cough. European Respiratory Journal. 59(6). 2100725–2100725. 39 indexed citations

3.

Ishihara, Hiroyuki, et al.. (2020). Design of phase 2b randomised controlled trial of S-600918, P2X3 receptor antagonist for refractory chronic cough. 2271–2271. 5 indexed citations

4.

Sanabria, Carlos, Elizabeth Migoya, Jay W. Mason, et al.. (2019). Effect of Cefiderocol, a Siderophore Cephalosporin, on QT/QTc Interval in Healthy Adult Subjects. Clinical Therapeutics. 41(9). 1724–1736.e4. 22 indexed citations

5.

Portsmouth, Simon, David van Veenhuyzen, Roger Echols, et al.. (2018). Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. The Lancet Infectious Diseases. 18(12). 1319–1328. 305 indexed citations breakdown →

6.

Portsmouth, Simon, David van Veenhuyzen, Roger Echols, et al.. (2017). Clinical Response of Cefiderocol Compared with Imipenem/Cilastatin in the Treatment of Adults with Complicated Urinary Tract Infections with or without Pyelonephritis or Acute Uncomplicated Pyelonephritis: Results from a Multicenter, Double-blind, Randomized Study (APEKS-cUTI). Open Forum Infectious Diseases. 4(suppl_1). S537–S538. 24 indexed citations

7.

Cuffe, Robert L., Carly Barnett, Catherine Granier, et al.. (2015). Missing CD4+ cell response in randomized clinical trials of maraviroc and dolutegravir. HIV Clinical Trials. 16(5). 170–177. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact